NO20051948L - Forbindelser som binder leukocytter og medisinsk sammensetning som inneholder forbindelsen i merket tilstand som aktiv ingrediens - Google Patents

Forbindelser som binder leukocytter og medisinsk sammensetning som inneholder forbindelsen i merket tilstand som aktiv ingrediens

Info

Publication number
NO20051948L
NO20051948L NO20051948A NO20051948A NO20051948L NO 20051948 L NO20051948 L NO 20051948L NO 20051948 A NO20051948 A NO 20051948A NO 20051948 A NO20051948 A NO 20051948A NO 20051948 L NO20051948 L NO 20051948L
Authority
NO
Norway
Prior art keywords
leukocytes
binding
compound
labeled
bind
Prior art date
Application number
NO20051948A
Other languages
English (en)
Inventor
Yoshifumi Shirakami
Ikuya Seki
Takayoshi Kawaguchi
Original Assignee
Nihon Mediphysics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd filed Critical Nihon Mediphysics Co Ltd
Publication of NO20051948L publication Critical patent/NO20051948L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

2005-06-15 Sammendrag O. nr. E40007 Det tilveiebringes en forbindelse som binder til leukocytter og som omfatter Met-Leu-Phe eller Nle-Leu-Phe som tjener som leukocyttbindende sete for en formylpeptidreseptor (FPR), en bindende del omfattende Ser- eller Thr som øker bindingsforholdene til monocytter og lymfocytter i alle leukocytter, en gruppe som kan merkes med et radioaktivt metall eller et paramagnetisk metall, og en spacer som binder disse som viser bindingsegenskaper som er spesifikke for alle leukocytter, det vil si neutrofiler, monocytter og lymfocytter både in vitro og in vivo, og som kan merkes med et radioaktivt metall eller et paramagnetisk metall. På grunn av disse egenskaper er forbindelsen meget brukbar ved SPECT-billeddiagnose, PET-billeddiagnose, MRI-billeddiagnose osv. der avbildingen gjennomføres på et sete med heftig leukocyttfiltrering ledsaget av en immunreaksjon hos et individ.
NO20051948A 2002-09-27 2005-04-21 Forbindelser som binder leukocytter og medisinsk sammensetning som inneholder forbindelsen i merket tilstand som aktiv ingrediens NO20051948L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002282229 2002-09-27
PCT/JP2003/012362 WO2004029080A1 (ja) 2002-09-27 2003-09-26 白血球結合性化合物およびその標識化合物を有効成分とする医薬組成物

Publications (1)

Publication Number Publication Date
NO20051948L true NO20051948L (no) 2005-06-15

Family

ID=32040529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051948A NO20051948L (no) 2002-09-27 2005-04-21 Forbindelser som binder leukocytter og medisinsk sammensetning som inneholder forbindelsen i merket tilstand som aktiv ingrediens

Country Status (16)

Country Link
US (1) US7220827B2 (no)
EP (1) EP1548027B1 (no)
JP (1) JP4279781B2 (no)
KR (1) KR100900178B1 (no)
CN (1) CN1684973A (no)
AT (1) ATE382632T1 (no)
AU (1) AU2003266655B2 (no)
CA (1) CA2498826A1 (no)
DE (1) DE60318466T2 (no)
DK (1) DK1548027T3 (no)
ES (1) ES2297268T3 (no)
IL (1) IL167518A (no)
NO (1) NO20051948L (no)
NZ (1) NZ538869A (no)
TW (1) TW200418880A (no)
WO (1) WO2004029080A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158532A0 (en) 2001-05-02 2004-05-12 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
TWI332404B (en) * 2004-03-25 2010-11-01 Nihon Mediphysics Co Ltd Medicinal composition containing peptide improved in water solubility and metal labeling efficacy thereof and medicinal formulation containing metal labeled peptide
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
KR100630489B1 (ko) 2006-01-10 2006-10-04 주식회사 펩트론 면역반응을 조절하는 펩타이드
WO2008098112A2 (en) 2007-02-07 2008-08-14 Purdue Research Foundation Positron emission tomography imaging method
CN101827631B (zh) * 2007-07-11 2013-04-24 得克萨斯系统大学董事会 用于成像中的粒子和标记物
JP6184101B2 (ja) * 2009-12-23 2017-08-23 サンフォード−バーナム メディカル リサーチ インスティテュート アネキシン１結合化合物に関する方法および組成物
CA2772767C (en) 2011-03-30 2019-02-26 Kyoto University Compound accumulating in inflammatory site, diagnostic agent containing the compound in labeled state and its precursor compound for labeling
CN114805598A (zh) * 2019-04-28 2022-07-29 广州市雷德生物科技有限公司 促进蛋白二聚体形成的拉链扣结构及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4986979A (en) 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
US5792444A (en) 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
NZ314680A (en) 1989-05-09 2000-08-25 Ortho Pharma Corp Treating localised infection or inflammation with a therapeutically conjugated chemotactic peptide
EP0814849A1 (en) 1995-10-19 1998-01-07 BRACCO International B.V. Magnetically labeled chemoattractants as targeted contrast agents in the nmr imaging of living tissues
WO2000066622A1 (en) * 1999-05-05 2000-11-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T20/dp178 and t21/dp107 are activators of human phagocyte formyl peptide receptors
AU2754600A (en) * 2000-02-04 2001-08-14 Us Health Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection
US6955884B2 (en) * 2000-10-17 2005-10-18 Trudeau Institute, Inc. Methods for identifying compounds that inhibit CD38 activity

Also Published As

Publication number Publication date
DK1548027T3 (da) 2008-05-13
EP1548027A4 (en) 2005-11-16
ATE382632T1 (de) 2008-01-15
CA2498826A1 (en) 2004-04-08
US20060057064A1 (en) 2006-03-16
CN1684973A (zh) 2005-10-19
JP4279781B2 (ja) 2009-06-17
EP1548027B1 (en) 2008-01-02
JPWO2004029080A1 (ja) 2006-01-26
US7220827B2 (en) 2007-05-22
DE60318466T2 (de) 2008-09-18
TW200418880A (en) 2004-10-01
DE60318466D1 (de) 2008-02-14
AU2003266655A1 (en) 2004-04-19
EP1548027A1 (en) 2005-06-29
KR20050053691A (ko) 2005-06-08
NZ538869A (en) 2006-09-29
AU2003266655B2 (en) 2009-01-08
KR100900178B1 (ko) 2009-06-02
IL167518A (en) 2009-11-18
WO2004029080A1 (ja) 2004-04-08
ES2297268T3 (es) 2008-05-01

Similar Documents

Publication Publication Date Title
NO20051948L (no) Forbindelser som binder leukocytter og medisinsk sammensetning som inneholder forbindelsen i merket tilstand som aktiv ingrediens
NO20064011L (no) Kontrastmidler for myokardial perfusjonsbilleddannelse
Krekorian et al. Imaging of T-cells and their responses during anti-cancer immunotherapy
SG152254A1 (en) Contrast agents for myocardial perfusion imaging
Jamous et al. Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases
Taher et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia
Mylonakis et al. Severe hepatitis associated with acute Ehrlichia canis infection in a dog.
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
EA200701362A1 (ru) Агонисты glp-1, композиции, способы и применения
DK0650527T3 (da) Forbedring af Borrelia burgdorferidiagnose og -profylakse
PA8684301A1 (es) Composiciones que contienen particulas magneticas de oxido de hierro, y uso de dichas composiciones en metodos de diagnostico por imágenes
WO2007065098A3 (en) Polyvalent chimeric ospc vaccinogen and diagnostic antigen
ATE555814T1 (de) Radioaktive mittel für die in vivo pet-bildgebung von ccr5
PA8684201A1 (es) Composiciones que contienen particulas magneticas de oxido de hierro, y uso de dichas composiciones en metodos de diagnostico por imágenes
Lankinen et al. 68 Ga-DOTAVAP-P1 PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones
WO2006032911A3 (en) Metalloproteinase inhibitor imaging agents
Van de Rijke Use of dyes in cariology.
Hall et al. Diagnosis of acute cardiac rejection with antimyosin monoclonal antibody, phosphorous nuclear magnetic resonance imaging, two-dimensional echocardiography, and endocardial biopsy.
MXPA04001113A (es) Formacion de imagenes simultaneas de perfusion cardiaca y agente formador de imagenes dirigido al receptor de vitronectina.
WO2002036173A3 (en) Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
ITMI20011706A0 (it) Agenti di contrasto radiografici ionici e non ionici, utilizzabili per l'indagine diagnostica combinata tramite raggi-x e risonanza magnetic
WO2007070827A3 (en) Contrast agents for myocardium perfusion imaging
DE59105603D1 (de) Monoklonale antikörper gegen den interleukin 2-rezeptor.
Kanderi et al. Molecular imaging in transplantation: basic concepts and strategies for potential application
Leung 99mTc-Interleukin-2

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application